Scott Simonet, Ph.D., Director, Research Department of Metabolic Disorders
...Scott Simonet, Ph.D.
...Scott Simonet, Ph.D.Director, Research Department of Metabolic Disorders Bone and Mineral MetabolismAmgen Scott received his Ph.D. in Molecular Biology and Biochemistry from the University of South Florida, College of Medicine in 1988.He
subsequently received an Individual National Research Service Award from the NIH
to perform postdoctoral training at the Gladstone Foundation Laboratories for Cardiovascular Disease at the University of California, San Francisco
, where he
studied regulation of apolipoprotein gene expression with John Taylor and Bob Mahley. Scott came to Amgen as a Research Scientist in February of 1992 and began to search for secreted proteins, which might have therapeutic utility.
In 1994 he
was part of a group contributing to Amgen
's Genomics program that identified and determined the function of a secreted protein in the TNFR Superfamily called osteoprotegerin (OPG).This group showed that OPG was a critical regulator of bone mineral density and acts by inhibiting the actions of RANKL on osteoclastogenesis.In 1998, this work received an award from the American Society of Bone and Mineral Research for Outstanding Research on the Pathophysiology of Osteoporosis
. Scott is currently Director of the Bone and Mineral Metabolism Research group in the Department of Metabolic Disorders at Amgen.He heads a group of 33 scientists working on developing novel therapies for osteoporosis and other bone related diseases.